COTEMPLA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cotempla, and what generic alternatives are available?
Cotempla is a drug marketed by Neos Theraps Inc and is included in one NDA. There are four patents protecting this drug.
The generic ingredient in COTEMPLA is methylphenidate. There are thirty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methylphenidate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cotempla
A generic version of COTEMPLA was approved as methylphenidate by MYLAN TECH VIATRIS on March 14th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for COTEMPLA?
- What are the global sales for COTEMPLA?
- What is Average Wholesale Price for COTEMPLA?
Summary for COTEMPLA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | COTEMPLA at DailyMed |
US Patents and Regulatory Information for COTEMPLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | 11,166,947 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-002 | Jun 19, 2017 | RX | Yes | No | 8,840,924 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | 8,840,924 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-003 | Jun 19, 2017 | RX | Yes | Yes | 8,840,924 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-002 | Jun 19, 2017 | RX | Yes | No | 9,072,680 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | 9,089,496 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | 9,072,680 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
